GA-STONEBRANCH
Stonebranch, a leading provider of service orchestration and automation solutions, announced another year of significant growth and innovation. Building on the unprecedented success of 2022, Stonebranch has continued to expand its offerings with major product updates and a host of strategic integrations that solidify its position as a leader in the IT automation industry.
New Customer and Partner Relationships Fuel Growth
In 2023, Stonebranch significantly expanded its customer base, welcoming a diverse range of new clients from various sectors, including finance, healthcare, manufacturing, and technology. In addition, new technology, channel, and consulting partnerships enhanced Stonebranch’s capabilities and market reach.
Reflecting on the company's growth, Stonebranch CEO Giuseppe Damiani stated, "2023 was a pivotal year for Stonebranch. Our ability to attract and retain such a diverse clientele speaks volumes about our users' trust and confidence in our solutions. As organizations continue to navigate the complexities of digital transformation, Stonebranch continues to be a provider and partner of choice. It's inspiring to see such a wide array of organizations recognize the value of our solutions, and we’re excited to shape the future of IT automation with them.”
Universal Automation Center Elevates User Experience
Stonebranch introduced substantial enhancements to the Universal Automation Center (UAC) platform in 2023, focusing on elevating the user experience and broadening the scope of automation capabilities for IT Ops, DataOps, MLOps, and CloudOps professionals. Key highlights include the launch of:
- Observability with OpenTelemetry: UAC 7.5 introduced the OpenTelemetry connector, which makes telemetry data available via the OpenTelemetry standards. This feature collects log, metric, and trace data from UAC and third-party applications integrated with the UAC. Then, it outputs that collected data to application performance management (APM) tools (like Splunk, Dynatrace, and DataDog) and observability/business intelligence tools (like Grafana, Jaeger, and PowerBI).
- SAP Enhanced View: UAC has always made it easy for IT Ops teams to manage SAP tasks. With the release of UAC 7.5, Stonebranch extended this ease to business users too, by rolling out a new guided interface that’s intuitive for anyone who usually works with SAP ECC or S/4HANA.
- Jobs-as-Code: Building on UAC’s DevOps capabilities, jobs-as-code enables developers to manage jobs and workflow configuration just like business application code — directly from their integrated development environment (IDE) of choice. Additionally, by integrating UAC with source control repositories like GitHub, GitLab, and Azure DevOps, developers can establish continuous delivery pipelines that offer version control, testing capabilities, and CI/CD best practices.
- Strategic Integrations for a Connected Ecosystem: 2023 also marked the debut of several pivotal integrations, reinforcing Stonebranch's commitment to foster a more connected and agile IT ecosystem. New integrations include SAP IBP and SAP HANA XSA, DBT, Azure Synapse, SQL OBDC, Fivetran, Databricks, Temenos, Oracle EBS, Azure AZ CLI, Google Cloud Composer, and Red Hat OpenShift. These additions enhance UAC’s ability to seamlessly connect and orchestrate across diverse IT landscapes, driving unparalleled efficiency and innovation.
"Innovation is at the heart of everything we do at Stonebranch,” says Stonebranch CTO Peter Baljet. “Our commitment as a product leader is driven by our customers' rapidly evolving needs as they adopt new IT landscape paradigms. Looking ahead, we aim to enable businesses with the full potential of automation, transforming their operations and setting new levels for agility, observability, and scalability."
Accolades Celebrate Excellence at Stonebranch
Stonebranch is consistently recognized for its innovation, leadership, and workplace culture by prestigious organizations and industry analysts. These accolades highlight Stonebranch's commitment to providing cutting-edge automation solutions and fostering a supportive, dynamic work environment. Some of the notable recognition Stonebranch received in 2023 include:
- Gartner®: The research and consulting firm recognized Stonebranch in a variety of reports and guides in 2023, such as the Market Guide for Service Orchestration and Automation Platforms (SOAPs), Data and Analytics Essentials: DataOps Report, Hype Cycle for IT Infrastructure and Operations (I&O), and more.
- EMA: As a Value Leader in the 2023 EMA Radar™ Report for Workload Automation and Orchestration, Stonebranch was recognized as a “top-tier orchestrator capable of automation on-premises and in the cloud.”
- G2: In its reports for workload automation and managed file transfer, the peer-review platform awarded Stonebranch three Leader badges, a High-Performer badge, and an Easiest Doing Business With badge.
- Atlanta Journal-Constitution / Energage: Based solely on employee feedback, Stonebranch was recognized as a Metro Atlanta Top Workplace for the second consecutive year.
“These awards and recognitions are not just milestones but also motivation for us at Stonebranch,” noted Damiani. “As we celebrate these achievements, we remain focused on pushing the boundaries of what's possible in IT automation and orchestration.”
About Stonebranch
Stonebranch builds IT orchestration and automation solutions that transform business IT environments from simple IT task automation into sophisticated, real-time business service automation. No matter the degree of automation, the Stonebranch platform is simple, modern, and secure. Using the Stonebranch Universal Automation Platform, enterprises can seamlessly orchestrate workloads and data across technology ecosystems and silos. Headquartered in Atlanta, Georgia, with points of contact and support throughout the Americas, Europe, and Asia, Stonebranch serves some of the world’s largest financial, manufacturing, healthcare, travel, transportation, energy, and technology institutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227593444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom